Kexing Biopharm Enters into Partnership with IQVIA to Boost Global Market Reach
Tuesday, August 12, 2025
Kexing Biopharm has entered into a strategic partnership with IQVIA.
The collaboration aims to speed up the global clinical development, regulatory approval, and commercialisation of Kexing’s innovative medicines and biosimilars, with a particular focus on Europe and other regulated international markets.
In recent years, Kexing Biopharm has advanced its globalisation strategy, combining strong research and development capabilities with flexible commercial operations. The company has successfully introduced several high-quality pharmaceutical products to overseas markets. Its licensed Nab-paclitaxel has gained swift approval and launch in several key regions. The company’s pipeline also targets areas such as antiviral treatments, oncology, immunosuppressants, and metabolic diseases.
Through this partnership, IQVIA will provide expertise in global clinical trial design, regulatory planning, and data-driven insights. Combining Kexing’s product portfolio with IQVIA’s worldwide operational network is expected to improve trial efficiency and speed up access to international markets.
The collaboration is set to strengthen Kexing’s capabilities in global development and support its goal of becoming a leading international biopharmaceutical company.
Source: prnewswire.com
